SME Times is powered by   
Search News
Just in:   • India forex reserves rise to $703.3 billion amid West Asia tensions  • India-Japan partnership to unlock construction data for AI-led urban development  • Centre doubles down on enhancing safety in flying training institutes  • India, US make progress on key issues in bilateral trade talks  • Sensex falls 983 points, Nifty slips below 24,000 as oil spike hits sentiment 
Last updated: 01 Feb, 2017  

cadila.thumb.jpg Cadila Healthcare net profit declines 34.6 pc in Q3

cadila.jpg
   Top Stories
» India forex reserves rise to $703.3 billion amid West Asia tensions
» Sensex falls 983 points, Nifty slips below 24,000 as oil spike hits sentiment
» Gross FDI flows to India accelerate to $90.8 billion, services sector dominates: Morgan Stanley
» Gold, silver rise up to 2 pc amid US-Iran ceasefire extension
» Crude oil prices down up to 2 pc as West Asia talks enter crucial negotiations
SME Times News Bureau | 01 Feb, 2017
Global pharmaceutical company Cadila Healthcare on Tuesday posted a 34.6 percent decline in its consolidated net profit to Rs 281.6 crore for the quarter ended December 31, 2016 as compared with Rs 430.5 crore in the year-ago period.

The company's consolidated total income from operations also dipped to Rs 2,363.8 crore during the quarter under review as compared with Rs 2,408.9 crore in a year-ago period.

On BSE, the stock settled at Rs 349.25, down 7.02 percent from the previous close.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹94.25
₹92.55
UK Pound
₹125.95
₹121.95
Euro
₹108.95
₹105.3
Japanese Yen ₹59.4 ₹57.6
As on 02 Apr, 2026
  Daily Poll
What is the biggest war impact on MSMEs?
 Export Disruption
 Raw Material Spike
 Freight Cost Surge
 Payment Delays
 Currency Volatility
 All
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter